Importer of Controlled Substances; Notice of Application, 30330-30331 [2013-12117]
Download as PDF
<![CDATA[
30330
Federal Register / Vol. 78, No. 99 / Wednesday, May 22, 2013 / Notices
TKELLEY on DSK3SPTVN1PROD with NOTICES
Therefore, in accordance with 21 CFR
§ 1301.34(a), this is notice that on
December 20, 2011, Wildlife
Laboratories Inc., 1401 Duff Drive, Suite
400, Fort Collins, Colorado 80524, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Etorphine (except HCl) (9056), a basic
class of controlled substance listed in
schedule I.
The company plans to manufacture
the above listed controlled substance for
sale to zoo and wildlife veterinarian
zoos and, for use with other animal and
wildlife applications.
Any bulk manufacturers who are
presently, or are applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR
§ 1301.43 and in such form as
prescribed by 21 CFR § 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 21, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745, all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR § 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–12109 Filed 5–21–13; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
16:59 May 21, 2013
Jkt 229001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Alltech
Associates, Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on March 28, 2013, Alltech
Associates, Inc., 2051 Waukegan Road,
Deerfield, Illinois 60015, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Gamma
Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
Heroin (9200) ...............................
Cocaine (9041) .............................
Codeine (9050) .............................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Fmt 4703
[FR Doc. 2013–12120 Filed 5–21–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
I
Importer of Controlled Substances;
Notice of Application
I
I
II
II
II
II
II
II
Pursuant to Title 21, Code of Federal
Regulations 1301.34 (a), this is notice
that on April 10, 2013, Arizona
Department of Corrections, ASPCFlorence, 1305 E. Butte Avenue,
Florence, Arizona 85132, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Pentobarbital (2270), a basic class of
controlled substance listed in schedule
II.
The facility intends to import the
above listed controlled substance for
legitimate use. Supplies of this
particular controlled substance are
inadequate and are not available in the
form needed within the current
domestic supply of the United States.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
listed in schedules I and II, which falls
under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 21, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
The company plans to import these
controlled substances for the
manufacture of reference standards.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I and II,
which falls under the authority of
section 1002(a)(2)(B) of the Act (21
U.S.C. 952(a)(2)(B)) may, in the
circumstances set forth in 21 U.S.C.
958(i), file comments or objections to
the issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR
§ 1301.43 and in such form as
prescribed by 21 CFR § 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 21, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic classes of
any controlled substances in schedules
I or II are, and will continue to be,
required to demonstrate to the Deputy
Frm 00064
Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Schedule
Drug
PO 00000
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Sfmt 4703
E:\FR\FM\22MYN1.SGM
22MYN1
30331
Federal Register / Vol. 78, No. 99 / Wednesday, May 22, 2013 / Notices
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–12117 Filed 5–21–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Meridian
Medical Technologies
By Notice dated March 7, 2012, and
published in the Federal Register on
March 13, 2013, 78 FR 15974, Meridian
Medical Technologies, 2555 Hermelin
Drive, St. Louis, Missouri 63144, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Morphine (9300), a basic class of
controlled substance listed in schedule
II.
The company manufactures a product
containing morphine in the United
States. The company exports this
product to customers around the world.
The company has been asked to ensure
that its product sold to European
customers meets standards established
by the European Pharmacopeia, which
is administered by the Directorate of the
Quality of Medicines (EDQM). In order
to ensure that its product will meet
European specifications, the company
seeks to import morphine supplied by
EDQM to use as reference standards.
This is the sole purpose for which the
company will be authorized by DEA to
import morphine.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Meridian Medical Technologies to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Meridian Medical Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR § 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–12121 Filed 5–21–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Alltech Associates, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 28, 2013,
Alltech Associates Inc., 2051 Waukegan
Road, Deerfield, Illinois 60015, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
TKELLEY on DSK3SPTVN1PROD with NOTICES
Drug
Schedule
Methcathinone (1237) ..................................................................................................................................................................................
N-Ethylamphetamine (1475) ........................................................................................................................................................................
N,N-Dimethylamphetamine (1480) ..............................................................................................................................................................
4-Methylaminorex (cis isomer) (1590) .........................................................................................................................................................
Alpha-ethyltryptamine (7249) ......................................................................................................................................................................
Lysergic acid diethylamide (7315) ...............................................................................................................................................................
2C-T-7 (2,5-Dimethoxy-4-(n)-Propylthiophenethylamine) (7348) ................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
Mescaline (7381) .........................................................................................................................................................................................
2C-T-2 (2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine)(7385) ................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (7391) ..............................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (7392) ..........................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (7395) ..............................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (7399) ................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) ..................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................
3,4-Methylenedioxymethamphetamine (7405) ............................................................................................................................................
4-Methoxyamphetamine (7411) ...................................................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine (7431) .................................................................................................................................................
Alpha-methyltryptamine (7432) ...................................................................................................................................................................
Bufotenine (7433) ........................................................................................................................................................................................
Diethyltryptamine (7434) .............................................................................................................................................................................
Dimethyltryptamine (7435) ..........................................................................................................................................................................
Psilocybin (7437) .........................................................................................................................................................................................
Psilocyn (7438) ............................................................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine (7439) ..............................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine (7455) ....................................................................................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine (7458) ....................................................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) ...............................................................................................................................................
VerDate Mar<15>2010
16:59 May 21, 2013
Jkt 229001
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
E:\FR\FM\22MYN1.SGM
22MYN1
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 78, Number 99 (Wednesday, May 22, 2013)]
[Notices]
[Pages 30330-30331]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-12117]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to Title 21, Code of Federal Regulations 1301.34 (a), this
is notice that on April 10, 2013, Arizona Department of Corrections,
ASPC-Florence, 1305 E. Butte Avenue, Florence, Arizona 85132, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as an importer of Pentobarbital (2270), a basic class of
controlled substance listed in schedule II.
The facility intends to import the above listed controlled
substance for legitimate use. Supplies of this particular controlled
substance are inadequate and are not available in the form needed
within the current domestic supply of the United States.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance listed in schedules I and II, which falls under the authority
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in
the circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than June 21, 2013.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted
[[Page 30331]]
in a previous notice published in the Federal Register on September 23,
1975, 40 FR 43745-46, all applicants for registration to import a basic
class of any controlled substance in schedules I or II are, and will
continue to be, required to demonstrate to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration pursuant to
21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d),
(e), and (f) are satisfied.
Dated: May 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-12117 Filed 5-21-13; 8:45 am]
BILLING CODE 4410-09-P
